Form 4: Esperion Therapeutics Director Acquires Shares
Statement of Changes in Beneficial Ownership
John Craig Thompson, a Director at Esperion Therapeutics, Inc., has acquired 79,873 shares of common stock.
Summary
- John Craig Thompson, a Director at Esperion Therapeutics, Inc., acquired 79,873 shares of common stock on May 28, 2026.
- The acquisition was made at a price of $0, indicating it was likely an award or grant.
- Following this transaction, Mr. Thompson beneficially owns 79,873 shares of common stock.
- The filing also includes a Power of Attorney granted by Craig Thompson to Sheldon Koenig and Benjamin Looker, authorizing them to execute SEC forms on his behalf.
- The awards vest in full on the earlier of May 28, 2027, or the Issuer's next annual meeting of stockholders following May 28, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports a routine share acquisition by a director without providing new financial or strategic information about the company.
Positives
- Director acquisition of shares can signal confidence in the company's future prospects.
- The acquisition of a significant number of shares (79,873) by a director is a positive indicator of insider commitment.
Risks
- The filing does not contain information about the company's financial performance or strategic direction, limiting the assessment of broader risks.
- The Power of Attorney document indicates that the attorney-in-fact is not assuming the undersigned's responsibilities to comply with Section 16 or Regulation 13D-G, implying potential compliance burdens for the individual.
Future Outlook
The awards vest in full on the earlier of May 28, 2027, or the Issuer's next annual meeting of stockholders following May 28, 2026. This indicates a future event related to the vesting of securities.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The acquisition of shares by a director at Esperion Therapeutics, Inc. is a routine event under SEC regulations, providing transparency to the market regarding insider holdings and transactions.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Craig Thompson has granted a Limited Power of Attorney to Sheldon Koenig and Benjamin Looker to execute SEC forms (Form ID, Form 3, Form 4, Form 5, Schedule 13D) on his behalf as an officer and/or director of Esperion Therapeutics, Inc. | 07/01/2025 | Ensures compliance with SEC filing requirements even in the absence of the reporting person, facilitating timely and accurate disclosures. |
Stakeholder Impact
- Shareholders: Increased transparency regarding director's holdings and potential confidence in the company.
- Management: The Power of Attorney streamlines compliance for management, reducing administrative burden.
- Regulatory Bodies: Ensures adherence to Section 16 of the Securities Exchange Act of 1934.
Next Steps
- Vesting of awards on the earlier of May 28, 2027, or the Issuer's next annual meeting of stockholders following May 28, 2026.
Key Dates
| Date | Description |
|---|---|
| 05/28/2026 | Transaction Date for acquisition of common stock and earliest transaction date. |
| 05/28/2027 | Vesting date for awards. |
| 06/01/2026 | Date of signature for the Form 4 filing. |
| 07/01/2025 | Effective date of the Power of Attorney. |
Keywords
Esperion Therapeutics, ESPR, Form 4, Insider Trading, Director, Stock Acquisition, Beneficial Ownership, SEC Filing, Securities Exchange Act
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.